Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. O'Shaughnessy on Negative TNBC Iniparib Results

August 23rd 2011

Dr. Joyce O'Shaughnessy from Baylor Sammons Cancer Center on Negative TNBC Iniparib Trial Results

Metformin May Decrease Diabetics' Breast Cancer Risk

August 22nd 2011

In postmenopausal diabetic women, metformin use was associated with lower ER and PR breast cancer incidence.

Dr. Tripathy Discusses HER2 Targeted Therapies

August 22nd 2011

Dr. Debu Tripathy from UC Norris Cancer Center Discusses HER2 Targeted Therapies

Yoga Benefits Patients With Breast Cancer

August 19th 2011

Patients with breast cancer who undertook yoga following radiotherapy derived physical and emotional benefi ts from the ancient Indian practice, according to research presented at ASCO.

Dr. Hendrix on Metastatic Cells in Microenvironments

August 18th 2011

Dr. Mary J. C. Hendrix from Northwestern University's Feinberg School of Medicine on Metastatic Tumor Cells in Microenvironments

Dr. Tripathy on Completing New Assays After Recurrence

August 18th 2011

Dr. Debu Tripathy from USC Norris Cancer Center on Completing New Assays After Recurrence

Breast Cancer Survivors Vulnerable to Long-Term Work Loss

August 17th 2011

Breast cancer survivors who stop working during chemotherapy may face the loss of long-term employment for several years after their diagnosis.

Dr. O'Shaughnessy on Avastin as Her Standard of Care

August 17th 2011

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on Avastin as Her Standard of Care

Survivorship Care Plans Do Not Improve Outcomes for Patients With Breast Cancer

August 16th 2011

A randomized trial comparing survivorship care plans with standard oncologist discharge visits in patients with breast cancer found no differences in outcomes among the groups.

Dr. Tripathy on the Future of Breast Cancer Meeting

August 16th 2011

Dr. Debu Tripathy from USC Norris Cancer Center Describes the Benefits of the PER Conferences

Dr. Wolff Discusses the Importance of HER2 Testing

August 15th 2011

Dr. Antonio C. Wolff from Sidney Kimmel Comprehensive Cancer Center Discusses the Importance of HER2 Testing

Dr. Tripathy on the Oncotype DX Assay Recurrence Score

August 15th 2011

Dr. Debu Tripathy from USC Norris Cancer Center on the Oncotype DX Assay Recurrence Score

Dr. O'Shaughnessy on Continued Access to Avastin

August 13th 2011

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on Continued Access to Avastin

Dr. Tripathy Discusses Breast Cancer Gene Profiling

August 12th 2011

Dr. Debu Tripathy from USC Norris Cancer Center Discusses Breast Cancer Gene Profiling

Dr. Tripathy Discusses Breast Cancer Biomarkers

August 11th 2011

Dr. Debu Tripathy from the USC Norris Comphrensive Cancer Center Discusses Breast Cancer Biomarkers

Computer-Aided Breast Cancer Detection

August 4th 2011

Recent study findings raise questions about how well computers interpret mammograms.

In Metastatic Breast Cancer, Eribulin Safe and Effective in All Ages

August 3rd 2011

An exploratory analysis of the phase III EMBRACE trial of eribulin mesylate in metastatic breast cancer found the survival benefit and toxicity profile to be independent of age.

Dr. Kris on Patient Acceptance of Mutation Testing

August 2nd 2011

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses Patient Acceptance of Mutation Testing

Judge Rules BRCA Genes Can Be Patented, Overturning Previous Decision

August 1st 2011

On July, 29, 2011, a US appeals court sided with Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes.

Exemestane Is a New Option for Prevention of Breast Cancer in Postmenopausal Women

August 1st 2011

Postmenopausal women at risk of breast cancer got good news from the MAP.3 trial results: Exemestane reduced their risk of invasive breast cancer by 65% compared with placebo.